טוען...
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-pacli...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3964033/ https://ncbi.nlm.nih.gov/pubmed/24672237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S58275 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|